je.st
news
Tag: symposium
Sunscreen Symposium Abstract Deadline Approaches
2015-01-09 06:00:00| Happi Breaking News
Presentations for consideration need to be in by Jan. 31.
Tags: abstract
approaches
deadline
symposium
Upcoming Symposium Includes Nutrient Management Topics
2015-01-08 23:15:00| National Hog Farmer
Source: Professional Nutrient Applicators Association of Wisconsin The 2015 Symposium and meeting of the Professional Nutrient Applicators Association of Wisconsin, The Midwest Forage Association and Wisconsin Custom Operators will be held Jan. 19-21 at the Chula Vista Resort in Wisconsin Dells, Wisc. read more
Tags: management
includes
topics
upcoming
PTS Coating Symposium to be held in Munich, Germany, Sept 16-17, 2015
2014-12-24 11:50:32| Paper - Topix.net
The traditional PTS Coating Symposium in Munich on September 16 - 17 is the leading event for manufacturers of coated paper and board, their suppliers and customers. The modern ambience of the new conference location Hotel Leonardo Royal combines the convenience of an in-house event with excellent service offers for all guests.
Tags: germany
held
sept
symposium
At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
2014-12-13 11:24:24| Biotech - Topix.net
Myriad Genetics, Inc. has announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.
Tags: san
studies
antonio
cancer
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium
2014-12-10 14:30:00| Merck.com - Corporate News
Dateline City: SAN ANTONIO 18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) SAN ANTONIO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response rate of 18.5 percent with KEYTRUDA, the companys anti-PD-1 therapy, as assessed by RECIST v1.1, central review (n=5/27), in PD-L1 positive, advanced triple-negative breast cancer one of the most aggressive forms of breast cancer. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558Claire Mulhearn, (908) 236-1118orInvestor:Joseph Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
san
presented
Sites : [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] next »